Comparing Medication Adherence Tools for the Direct Oral Anticoagulants Rivaroxaban and Apixaban

被引：0
|
作者：
Castellucci, Lana A.
Chiang, Philip
Pecarskie, Amanda
Le Gal, Gregoire
Rodger, Marc
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3713
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban, edoxaban - addition - EML
    SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 339 - 355
  • [2] Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban
    Sattari, Maryam
    Lowenthal, David T.
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (04) : 332 - 338
  • [3] Effect of the Direct Oral Anticoagulants Rivaroxaban and Apixaban on the Disposition of Calcineurin Inhibitors in Transplant Recipients
    Vanhove, Thomas
    Spriet, Isabel
    Annaert, Pieter
    Maertens, Johan
    Van Cleemput, Johan
    Vos, Robin
    Kuypers, Dirk
    THERAPEUTIC DRUG MONITORING, 2017, 39 (01) : 77 - 82
  • [4] Management of severe bleeding due to direct oral anticoagulants (DOACs): apixaban, dagibatran, rivaroxaban
    Sagourin, Pauline
    Martelli, Sonia
    Lefebure, Anne
    Tesmoingt, Chloe
    Faille, Dorothee
    Ajzenberg, Nadine
    Casalino, Enrique
    Arnaud, Philippe
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 215 - 216
  • [5] EFFICACY AND SAFETY OF THE NOVEL ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN AND APIXABAN
    Elnadoury, Ola
    Yuen, Meggie
    Oh, Erin
    Abraham, Teena
    Saad, Nasser
    CRITICAL CARE MEDICINE, 2014, 42 (12)
  • [6] Medication Adherence to Direct Oral Anticoagulants: Extent and Impact of Side Effects
    van de Steeg, Bas J. W.
    Esselink, Anne C.
    de Wit, Hugo A. J. M.
    Kramers, Cornelis
    van den Bemt, Bart J. F.
    PATIENT PREFERENCE AND ADHERENCE, 2024, 18 : 1779 - 1788
  • [7] Electronically monitored medication adherence and behavioural patterns of direct oral anticoagulants
    Kolmanova, E.
    Dvorackova, S.
    Sisakova, M.
    Brabec, M.
    Penka, M.
    Kala, P.
    Maly, J.
    Mala-Ladova, K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (01) : 296 - 296
  • [8] Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
    Steiner, T.
    Boehm, M.
    Dichgans, M.
    Diener, H. -C.
    Ell, C.
    Endres, M.
    Epple, C.
    Grond, M.
    Laufs, U.
    Nickenig, G.
    Riess, H.
    Roether, J.
    Schellinger, P. D.
    Spannagl, M.
    Veltkamp, R.
    CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (06) : 399 - 412
  • [9] Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
    T. Steiner
    M. Böhm
    M. Dichgans
    H.-C. Diener
    C. Ell
    M. Endres
    C. Epple
    M. Grond
    U. Laufs
    G. Nickenig
    H. Riess
    J. Röther
    P. D. Schellinger
    M. Spannagl
    R. Veltkamp
    Clinical Research in Cardiology, 2013, 102 : 399 - 412
  • [10] Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays
    Gosselin, R.
    Grant, R. P.
    Adcock, D. M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (05) : 505 - 513
12345